March 25, 2021
Japan’s all-important reimbursement policy panel on March 24 endorsed the appraisal results for Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) and GlaxoSmithKline’s COPD drug Trelegy (fluticasone furoate + umeclidinium + vilanterol) - the first two products that came out of the...read more